Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Reissig, TM; Uhrig, S; Jost, PJ; Luchini, C; Vicentini, C; Liffers, ST; Allgauer, M; Adsay, V; Scarpa, A; Lawlor, RT; Frohling, S; Stenzinger, A; Kloppel, G; Schildhaus, HU; Siveke, JT.
MCL1 as putative target in pancreatoblastoma
VIRCHOWS ARCH. 2022;
Doi: 10.1007/s00428-022-03349-w
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Jost Philipp
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Pancreatoblastoma (PB) is a rare tumor of the pancreas. In case of metastases, the treatment options are sparse and targeted approaches are not developed. We here evaluate MCL1 amplification as a putative target in PB. Thirteen samples from adult (10/13) and pediatric patients (3/13) were collected. Three of these samples had been previously subjected to whole-exome sequencing (2 cases) or whole-genome sequencing (1 case) within a precision oncology program (NCT/DKTK MASTER), and this analysis had shown copy number gains of MCL1 gene. We established a fluorescence in situ hybridization (FISH) test to assess the copy number alterations of MCL1 gene in 13 formalin-fixed paraffin-embedded PBs, including the 3 cases assessed by genome sequencing. FISH analysis showed the amplification of MCL1 in 2 cases (both were adult PB), one of which was a case with the highest copy number gain at genomic analysis. In both cases, the average gene copy number per cell was >= 5.7 and the MCL1/1p12 ratio was >= 2.4. Our data support MCL1 as a putative target in PB. Patients with MCL1-amplified PB might benefit from MCL1 inhibition. Sequencing data is useful to screen for amplification; however, the established FISH for MCL1 can help to determine the level and cellular heterogeneity of MCL1 amplification more accurately.
- Find related publications in this database (Keywords)
-
MCL1
-
Amplification
-
FISH
-
Whole-genome sequencing
-
NCT MASTER
-
Pancreatoblastoma